烟台{风湿}性多肌痛的治疗方案青岛治{风湿}花多少钱,济宁山东治风湿性关节炎哪里好,聊城得风湿怎么治疗,菏泽产后身痛见风是不是更厉害,菏泽得了年轻人风湿怎么办好,菏泽风湿性关节炎发病会有什么感觉,淄博治疗{风湿}的医院哪家好

BEIJING, Aug. 30 (Xinhua) -- China's second moon orbiter, the Chang'e-2, has arrived in outer space about 1.5 million km away from Earth and is now orbiting the second Lagrange Point (L2), where gravity from the sun and Earth balances the orbital motion of a satellite, Chinese scientists said Tuesday.Chang'e-2 entered L2's orbit at 11:27 p.m. last Thursday after spending 77 days traveling away from its previous orbital path around the moon, according to the State Administration of Science, Technology and Industry for National Defence (SASTIND).The SASTIND said that China is now the world's third country or organization to successfully put a spacecraft into orbit around L2, after the European Space Agency (ESA) and the National Aeronautics and Space Administration (NASA) of the United States.The Chang'e-2 orbiter will carry out exploration activities around L2 in the coming year, SASTIND said.There are five so-called "Lagrange Points" about 1.5 million km way from the Earth in the exact opposite direction from the sun. Putting a spacecraft at any of these points allows it to stay in a fixed position relative to the Earth and sun with a minimal amount of energy needed for course correction.The orbiter completed all of its assigned tasks after blasting off on Oct. 1, 2010, according to the SASTIND. Although the orbiter was only supposed to remain in space for six months, the SASTIND decided to assign additional tasks to it, as it still had fuel in its reserve tanks.Traveling into outer space from the moon's orbit was one of the orbiter's most important missions, according to the SASTIND.Before arriving at its current position in outer space, the Chang'e-2 took photos of the northern and southern poles of the moon. It then descended to a lower orbit, approximately 15 km away from the moon's surface, where it captured high-resolution images of the Sinus Iridum, or "Bay of Rainbows," an area where future moon probes may land.The SASTIND is reportedly planning to launch measure and control stations into outer space by the end of the second half of next year. The Chang'e-2 will be used to test the two stations' functionality at that time.China's ambitious three-stage moon mission will include a moon landing, as well as the launch of a moon rover during the second stage, which is scheduled to take place in 2012. During the third phase, another rover will land on the moon and return to Earth with lunar soil and stone samples for scientific research around 2017.China does not currently have a timetable in place for a manned moon landing. It launched its first lunar probe, the Chang'e-1, in October 2007.In 2003, China became the third country after Russia and the United States to send a human into space. Two more manned space missions followed, the most recent of which took place in 2008.0 The Chang'e probes are named after the Chinese legendary goddess of the moon.

BEIJING, Aug. 24 (Xinhuanet) -- Married patients are more likely than single ones to survive 15 years after heart surgery, according to a study online in the Health Psychology.Researchers of the study tracked 225 people who underwent coronary bypass surgery from 1987 to 1990. They found that 124 patients of them, or about 55 percent, survived for at least the next 15 years. And 61 percent of the married patients and 30 percent of the unmarried survived.Kathleen King, lead author of study, said that the close connection to another person in a marriage lengthened patients’ lives."Marriage gives you purpose in life, and feeling like you have a reason to live is an important part of doing the things you need to do to stay alive," Harry T. Reis, co-author of the study, said. "Married people also help each other; remind each other it's time to take their pills. And they probably eat healthier."However, the marriage quality had different effects on the survival odds between men and women. Men who had bypass surgery lived longer by virtue of simply being married, regardless of how happy or miserable the union, but the marriage quality had more impact on women's survival after surgery. 83 percent of the happily married women had survived, compared with 28 percent of the less happily married women and 27 percent of the single women. Among the men, 83 percent of the happily married were still alive, compared with 60 percent of the less happily married and 36 percent of the single."The most dramatic thing to me is [that] just being married, especially if you had a happy marriage, had that big an effect 15 years later," King told ABCNews.com.Marriage does not only have a positive effect on the survival of patients after heart surgery, but also benefits patients with other diseases.In recent years, a number of studies have showed several apparent health benefits of marriage. For instance, it might slightly add the odds of survival from colon cancer and help reduce pain in rheumatoid arthritis patients.

SYDNEY, July 15 (Xinhua) -- The world's first drug to increase life expectancy of people with advanced melanoma has been approved for use in Australia, local media reported on Friday.The breakthrough drug Yervoy got approval from the Therapeutics Good Association (TGA) on Friday amid hopes it could add two years to the life of people with the most lethal form of skin cancer but for whom other treatments have failed, the Australian Associated Press (AAP) said.Clearance for the drug's use in Australia follows similar approvals by the U.S. health regulator in March.Yervoy works by attacking and destroying cancer cells.Patients are hooked up to an intravenous drip once every three weeks for a total of four doses.Professor Peter Hersey, consultant immunologist to the Melanoma Institute Australia, said no other drug had improved survival rates like Yervoy."Not all patients respond to it but those who do have a good chance of living longer than they would have otherwise," Hersey told AAP.While it may improve survival rates, Yervoy can produce side effects from diarrhea and vomiting to serious blood infections and kidney failure.The average survival time for people with advanced melanoma is just six months.A global study of 676 people with melanoma found that 45 percent of patients given Yervoy were still alive after one year, according to AAP.More than 20 percent lived at least two years, with a small number managing to survive for six years.A separate study, published in June, which showed similarly improved survival rates for patients with newly diagnosed advanced melanoma, has raised hopes that Yervoy could be made more widely available.Melanoma is the fourth most common cancer in Australia, with 10, 300 people diagnosed each year.